Eating disorders are on the rise. GLP-1s could make things worse.
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…
Contenu original affiche; la traduction localisee n'est pas encore disponible.
Ce qui s'est passé
GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister—a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023—by a whopping 71%. By 2023,…
Pourquoi c'est important
The development may change operating conditions or market expectations around AI. Further confirmation and measurable outcomes matter.
Entités concernées
Voir les preuves
1 articles · 1 publication d'origine · 1 independantes
- MIT Technology ReviewSource primaire · Confirme · EN · 100%Eating disorders are on the rise. GLP-1s could make things worse. ↗
Affirmations
- Eating disorders are on the rise. GLP-1s could make things worse. Signalé
Divergences
Aucune divergence importante détectée dans les preuves disponibles.
Chronologie
- Premier signalement
Mouvement de marché suivant l'événement
La réaction du marché n'est pas encore disponible pour cet actif et cette fenêtre.